SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxiss Investor Day and upcoming FDA reviews are drawing attention, with traders focused on launch preparations and the commercial potential of ulixacaltamide for essential tremor and relutrigine for rare epilepsies, alongside expected EMERALD data. Sentiment is largely bullish on the catalysts, while some caution that approvals, launch uptake, and relutrigines review timing remain uncertain.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas anticipated Phase 3 APPROACH topline results for HLP003 in major depressive disorder, a binary clinical catalyst that traders see as potentially pivotal for the companys psychedelic-therapy prospects. Bulls emphasize its adjunctive design and potential for shorter clinic sessions, while skeptics point to uncertainty about whether Phase 2 efficacy will hold up and raise concerns about dilution and governance.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Positive interim REGAIN data in recurrent glioblastoma presented at SNO is driving attention, with traders reacting enthusiastically to the early responses and looking to the investor call for detail on durability, safety, and the path to a larger dataset. Some caution that the results are still early and debate whether the excitement is already reflected in the share price.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

The FAAs nationwide ground stop, attributed to an air-traffic-control communications outage, disrupted flights and pressured airline stocks including Delta. Traders debate whether the cancellations will materially hurt results or prove temporary; political and cyberattack explanations circulating in the community remain speculation, with no evidence cited to support them.

Shiba Inu (SHIB) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Shiba Inu has a current supply of 589,495,699,860,951.91490568 with 589,238,106,731,035.4551592 in circulation. The last known price of Shiba Inu is 0.00000379 USD and is down -10.85 over the last 24 hours. It is currently trading on 1128 active market(s) with $78,538,817.41 traded over the last 24 hours. More information can be found at https://shibatoken.com/.

Shiba Inu

SHIB is drawing attention amid frustration over its prolonged weakness and lack of momentum, with traders citing its large token supply, limited utility, and fading meme-coin hype. Views are split between holders accumulating dips and hoping for a revival, and skeptics expecting further declines; repeated chart commentary describes consolidation with a bearish tilt.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,112,050. The last known price of Bitcoin is 63,437.21016941 USD and is down -7.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $45,086,253,428.50 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and subsequent bounce have sparked a debate over whether oversold conditions and support mark a near-term bottom or whether bearish momentum points to further losses. Traders speculate that liquidations, ETF outflows, and broader risk-off concerns are adding pressure, but no single cause dominates the discussion.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Rhythm Pharmaceuticals Inc.

Reports of AstraZenecas non-binding acquisition offer have fueled buyout speculation, with traders discussing a possible counterbid or second suitor and arguing over whether the deal will proceed at a higher valuation. The transaction remains uncertain, and some traders caution that the offer is unconfirmed and may not close.

Barclays Bank Plc engages in providing commercial banking services. It offers personal, premier, business, and corporate banking products and services to its customers. Its services include current accounts, savings, investments, mortgages, loans, insurance, credit cards, and online banking. The company was founded on October 4, 1971 and is headquartered in London, the United Kingdom.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

Traders are focused on VXX as a hedge against a possible equity pullback and renewed volatility, with geopolitical and macro risks cited as concerns. The community is divided between expecting a volatility breakout and arguing that VXXs futures-rolling decay makes spikes likely to fade.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

The FDA issued a Complete Response Letter for Summits ivonescimab application in EGFR-mutated lung cancer, citing the lack of statistically significant overall-survival benefit despite strong progression-free-survival results. Traders reacted with heavy bearishness and concern about lost near-term commercial prospects, while some see the decision as limited to this indication and point to HARMONi-3 and the broader pipeline as remaining catalysts.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcaths strong third-quarter results and higher full-year revenue outlook have driven attention, with traders cheering accelerating HEPZATO sales and renewed commercial momentum. Some remain cautious about the outlooks assumptions and slower breast-cancer trial enrollment.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


Toepaw

Frek